VNDA Financial Facts
Income (loss) from operations: -653KResearch and development: 7.29M
See Full Income Statement
Property and equipment, net: 4.73M
Total assets: 208.44M
See Full Balance Sheet
Vanda Pharma (VNDA) Earnings
|
Expand Research on VNDA
| Next EPS Date | 8/5/26 | EPS Growth Rate | -30.4% |
|---|---|---|---|
| Average EPS % Beat Rate | -37.6% | Revenue Growth Rate | +17.1% |
| Average % Move 1-Wk after EPS | -14.4% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/5/26  |
Q226 | N/A | -$0.60 | N/A | N/A | $61.58M | = | N/A | N/A | ||
| 5/6/26 | Q126 | -$0.82 | -$0.69 | -$0.13 | $51.72M | $55.04M | = |  | | Details | |
| 2/11/26 | Q425 | -$1.81 | -$0.98 | -$0.83 | $33.22M | $59.28M | = | | | Details | |
| 10/29/25 | Q325 | -$0.38 | -$0.43 | +$0.05 | $56.26M | $58.83M | = | | | Details | |
| 7/31/25 | Q225 | -$0.46 | -$0.29 | -$0.17 | $52.59M | $55.1M | = | | | Details | |
| 5/7/25 | Q125 | $0.00 | -$0.02 | +$0.02 | $50.04M | $61.02M | = | | | Details | |
| 5/2/25 |
Q125 | N/A | -$0.02 | N/A | N/A | $61.02M | = | N/A | N/A | ||
| 4/30/25 |
Q125 | N/A | -$0.02 | N/A | N/A | $61.02M | = | N/A | N/A |
